Association between the Achievement of Target Range CKD-MBD Markers and Mortality in Prevalent Hemodialysis Patients in Taiwan by Using the Kidney Disease: Improving Global Outcomes Clinical Guidelines

Table 4

Odds ratio of all-cause and CV mortality by achievement of KDIGO clinical guideline, P target.

	OR (95% CI)
	Model 1		Model 2		Model 3
P (mg/dL), all-cause
<2.4	1.61 (0.80~3.22)	0.17	1.16 (0.42~3.17)	0.77	0.89 (0.18~4.35)	0.88
2.4~4.7	1.00		1.00		1.00
>4.7	1.13 (0.82~1.55)	0.47	1.76 (1.19~2.60)	0.004	1.82 (1.17~2.82)	0.007
P (mg/dL), CV
<2.4	2.13 (0.62~7.31)	0.23	1.78 (0.36~8.88)	0.48	4.70 (0.69~31.9)	0.11
2.4~4.7	1.00		1.00		1.00
>4.7	1.60 (0.86~2.97)	0.13	2.59 (1.27~5.32)	0.009	2.62 (1.19~5.76)	0.01

Logistic regression model:
Model 1: unadjusted.
Model 2: adjusted for age, sex, hemodialysis vintage, etiology of renal failure, EPO, vitamin-D analogs, antihypertensive agent, iron use, and parathyroidectomy.
Model 3: model 2 + baseline laboratory results (albumin, hemoglobin, cholesterol, triglyceride, glucose (fasting), ferritin, Ca, iPTH, potassium, uric acid, urea, and cardiac-thoracic ratio).